Palvella Therapeutics

Palvella Therapeutics

Yahoo Finance • 15 days ago

Palvella Therapeutics to Host Second Quarter 2026 Financial Results and Corporate Update Conference Call on August 4, 2026

WAYNE, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare... Full story

Yahoo Finance • 27 days ago

Palvella Therapeutics (PVLA) Submits Initial Module of NDA For QTORIN

Palvella Therapeutics Inc. (NASDAQ:PVLA) is one of the 10 affordable biotech stocks to buy right now. On June 29, Palvella Therapeutics Inc. (NASDAQ:PVLA) disclosed that it filed the initial module of its New Drug Application with the FDA... Full story

Yahoo Finance • last month

Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed modules of the NDA before the full application is submitted FDA previously granted Breakthrough Therapy and Fast Track des... Full story

Yahoo Finance • last month

What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally

Kathleen Goin, Chief Operating Officer of Palvella Therapeutics (NASDAQ:PVLA), reported the exercise of 4,302 stock options immediately converted and sold as common shares for a transaction value of approximately $476,000 according to the... Full story

Yahoo Finance • 2 months ago

FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations

FDA’s rolling review process is intended to facilitate expedited review, enabling FDA to begin evaluating completed sections of the NDA before the full application is submitted Palvella remains on track to complete the NDA submission in t... Full story

Yahoo Finance • 2 months ago

Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

WAYNE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients... Full story

Yahoo Finance • 3 months ago

Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market

Palvella Therapeutics Inc. Uplisting reflects Palvella’s continued progress advancing potential first-in-disease therapies for serious, rare skin diseases and vascular malformations WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Palvella T... Full story

Yahoo Finance • 3 months ago

Roivant Sciences Ltd. (ROIV): One of the Best Stocks to Buy According to Joe Edelman

We just covered the Billionaire Joe Edelman’s 10 Stock Picks with Huge Upside Potential and Roivant Sciences Ltd. (NASDAQ:ROIV) ranks 8th on this list. Roivant Sciences Ltd. (NASDAQ:ROIV) recently won a major legal battle. In March, Roiva... Full story

Yahoo Finance • 4 months ago

Eli Lilly and Company (LLY): One of the Top Low Risk High Growth Stocks?

We just covered the 14 Best Low Risk High Growth Stocks to Buy Right Now and Eli Lilly and Company (NYSE:LLY) ranks 2nd on this list. Eli Lilly and Company (NYSE:LLY) is often referred to as the leading contender to become the first trill... Full story

Yahoo Finance • 4 months ago

Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations

Review delineates differences in clinical strategies between microcystic and macrocystic lymphatic malformations to guide disease-specific clinical trial design and treatment approaches Manuscript emphasizes the importance of early therap... Full story

Yahoo Finance • 5 months ago

Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

Palvella Therapeutics Inc. Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth f... Full story

Yahoo Finance • 5 months ago

Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin

Patent strengthens global intellectual property protection for QTORIN™ rapamycin, Palvella’s lead product candidate from the QTORIN™ platform, in development for serious, rare skin diseases and vascular malformations with no FDA-approved t... Full story

Yahoo Finance • 5 months ago

Palvella Prices $200 Mln Upsized Offering To Advance Late-Stage QTORIN Pipeline

(RTTNews) - Palvella Therapeutics, Inc. (PVLA) has priced an upsized public offering of 1.6 million shares of common stock at $125.00 per share, with expected gross proceeds of $200 million before underwriting discounts and expenses. Unde... Full story

Yahoo Finance • 5 months ago

Palvella Therapeutics Announces Pricing of Upsized Public Offering

WAYNE, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from... Full story

Yahoo Finance • 6 months ago

Palvella Therapeutics price target raised to $255 from $200 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Palvella Therapeutics (PVLA) to $255 from $200 and keeps a Buy rating on the shares. Phase 3 SELVA data, with the mLM-IGA primary endpoint demonstrating a statistically significant 2.13-poi... Full story

Yahoo Finance • 6 months ago

Stocks Settle Higher as AI Disruption Fears Ease

The S&P 500 Index ($SPX) (SPY) on Tuesday closed up +0.77%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.76%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.09%.  March E-mini S&P futures (ESH26) rose +0.76%, and March... Full story

Yahoo Finance • 6 months ago

Stocks Rally as AI-Fueled Worries Ease

The S&P 500 Index ($SPX) (SPY) today is up +0.50%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.75%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.90%.  March E-mini S&P futures (ESH26) are up +0.45%, and March E-mini Nasdaq f... Full story

Yahoo Finance • 6 months ago

Stocks Rebound as Software Stocks Recover

The S&P 500 Index ($SPX) (SPY) today is up +0.17%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.64%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.47%.  March E-mini S&P futures (ESH26) are up +0.20%, and March E-mini Nasdaq f... Full story

Yahoo Finance • 6 months ago

Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations 

WAYNE, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients... Full story

Yahoo Finance • 6 months ago

Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis

Publication includes a systematic review of 24 studies describing off-label cutaneous application of statins in porokeratosis Preliminary case reports suggesting clinical benefit underscore unmet need for development of a standardized, FDA... Full story